A Phase 2 Study to Evaluate the Efficacy and Safety of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP)
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Dizal Pharmaceuticals
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Overall response rate (4 weeks)
Overview
Brief Summary
This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is patients with primary ITP who had failed to respond or relapsed after receiving at least one standard therapy. Participants who meet the inclusion criteria and do not meet the exclusion criteria will be randomized to different dose groups.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and female participants ≥ 18 years of age.
- •Diagnosed with persistent or chronic primary ITP, and an average of two platelet counts \< 30 × 10⁹/L.
- •Have failed at least one standard treatment for ITP (glucocorticoids and/or IVIG).
- •Adequate bone marrow reserve and organ functions.
- •Willing to comply with contraceptive restrictions.
Exclusion Criteria
- •Have evidence of secondary causes of immune thrombocytopenia.
- •Have a history of coagulation disorders other than ITP, such as disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura.
- •Any of previous or current treatment prohibited by protocol.
- •Any of severe cardiac abnormalities.
- •Active infection.
- •Poorly controlled gastrointestinal disorder, inadequate absorption of medication or other systemic diseases.
- •Known allergy to DZD8586 drug excipients or other chemical analogues.
- •Pregnant or breastfeeding female participants.
Arms & Interventions
DZD8586 dose level 1
Administered orally, once daily.
Intervention: DZD8586 dose level 1 (Drug)
DZD8586 dose level 2
Administered orally, once daily.
Intervention: DZD8586 dose level 2 (Drug)
DZD8586 dose level 3
Administered orally, once daily.
Intervention: DZD8586 dose level 3 (Drug)
Outcomes
Primary Outcomes
Overall response rate (4 weeks)
Time Frame: within 4 weeks
The proportion of patients with platelet counts ≥ 50 × 10⁹/L on 2 consecutive visits (with an interval of at least 7 days) within 4 weeks.
Secondary Outcomes
- Incidence and severity of Adverse Events (AEs)(30 days after the last dose)
- Overall response rate (12 weeks)(within 12 weeks)
- Durable response rate(within 24 weeks)
- Time to response(within 24 weeks)